New-Onset Refractory Status Epilepticus (NORSE): The Queen Square Neuro-ICU experience

•We found no difference in outcome between those with NORSE and non-NORSE SE.•Similarly there were no differences in the sub-group analysis of the NORSE cohort.•This raises questions as to the clinical utility and validity of the term ‘NORSE’. The introduction and widespread adoption of the term ‘NO...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Epilepsy & behavior 2021-12, Vol.125, p.108387-108387, Article 108387
Hauptverfasser: Neligan, Aidan, Kerin, Bellami, Walker, Matthew C, Rajakulendran, Sanjeev
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•We found no difference in outcome between those with NORSE and non-NORSE SE.•Similarly there were no differences in the sub-group analysis of the NORSE cohort.•This raises questions as to the clinical utility and validity of the term ‘NORSE’. The introduction and widespread adoption of the term ‘NORSE’ – new-onset refractory status epilepticus – raises both fundamental conceptual and pragmatic questions. We studied a cohort of patients with ‘NORSE’ at the National Hospital for Neurology and Neurosurgery to investigate the clinical features, treatment responses, and outcomes with a focus on sub-group analysis. We identified 26 cases of ‘NORSE’. There was no difference in prognosis between ‘NORSE’ and non-‘NORSE’ RSE, nor in any sub-analysis in the ‘NORSE’ cohort. We discuss the utility and validity of the term NORSE as a descriptor for a subgroup with RSE in whom the underlying etiologies are heterogeneous and pathophysiological mechanisms are unknown.
ISSN:1525-5050
1525-5069
DOI:10.1016/j.yebeh.2021.108387